nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—ADRA1B—vas deferens—prostate cancer	0.0439	0.267	CbGeAlD
Loxapine—HTR7—vas deferens—prostate cancer	0.0256	0.155	CbGeAlD
Loxapine—CHRM3—ureter—prostate cancer	0.0206	0.125	CbGeAlD
Loxapine—HRH4—bone marrow—prostate cancer	0.00551	0.0335	CbGeAlD
Loxapine—HTR2A—urine—prostate cancer	0.00396	0.0241	CbGeAlD
Loxapine—DRD4—testis—prostate cancer	0.0032	0.0194	CbGeAlD
Loxapine—Cyclizine—SULT1E1—prostate cancer	0.00316	0.244	CrCbGaD
Loxapine—CHRM5—epithelium—prostate cancer	0.00315	0.0192	CbGeAlD
Loxapine—CHRM2—prostate gland—prostate cancer	0.00294	0.0179	CbGeAlD
Loxapine—ADRB1—prostate gland—prostate cancer	0.00278	0.0169	CbGeAlD
Loxapine—CHRM1—prostate gland—prostate cancer	0.00268	0.0163	CbGeAlD
Loxapine—ADRA1B—renal system—prostate cancer	0.00267	0.0162	CbGeAlD
Loxapine—CHRM4—testis—prostate cancer	0.00242	0.0147	CbGeAlD
Loxapine—CHRM3—prostate gland—prostate cancer	0.0024	0.0146	CbGeAlD
Loxapine—ADRA1A—prostate gland—prostate cancer	0.0022	0.0134	CbGeAlD
Loxapine—ADRA2C—prostate gland—prostate cancer	0.0021	0.0128	CbGeAlD
Loxapine—ADRA2C—seminal vesicle—prostate cancer	0.00177	0.0108	CbGeAlD
Loxapine—HRH1—prostate gland—prostate cancer	0.0017	0.0104	CbGeAlD
Loxapine—HTR7—epithelium—prostate cancer	0.00168	0.0102	CbGeAlD
Loxapine—ADRA2A—prostate gland—prostate cancer	0.00167	0.0102	CbGeAlD
Loxapine—CHRM3—renal system—prostate cancer	0.00163	0.00994	CbGeAlD
Loxapine—HTR1A—renal system—prostate cancer	0.00163	0.0099	CbGeAlD
Loxapine—ADRA1A—epithelium—prostate cancer	0.00162	0.00984	CbGeAlD
Loxapine—CHRM3—urethra—prostate cancer	0.00161	0.00976	CbGeAlD
Loxapine—HTR7—renal system—prostate cancer	0.00156	0.00946	CbGeAlD
Loxapine—ADRA1A—renal system—prostate cancer	0.0015	0.00912	CbGeAlD
Loxapine—HRH2—lymph node—prostate cancer	0.00143	0.00872	CbGeAlD
Loxapine—ADRA2C—renal system—prostate cancer	0.00143	0.00869	CbGeAlD
Loxapine—ADRA2A—seminal vesicle—prostate cancer	0.00142	0.00861	CbGeAlD
Loxapine—ADRA2C—urethra—prostate cancer	0.0014	0.00854	CbGeAlD
Loxapine—SLC6A3—testis—prostate cancer	0.00129	0.00786	CbGeAlD
Loxapine—HRH1—epithelium—prostate cancer	0.00125	0.00761	CbGeAlD
Loxapine—HRH1—urethra—prostate cancer	0.00114	0.00694	CbGeAlD
Loxapine—ADRA2A—urethra—prostate cancer	0.00112	0.00681	CbGeAlD
Loxapine—CHRM3—testis—prostate cancer	0.00106	0.00642	CbGeAlD
Loxapine—HTR2A—epithelium—prostate cancer	0.00105	0.00636	CbGeAlD
Loxapine—SLC6A2—testis—prostate cancer	0.00104	0.00634	CbGeAlD
Loxapine—HTR7—testis—prostate cancer	0.00101	0.00611	CbGeAlD
Loxapine—HTR2A—renal system—prostate cancer	0.00097	0.0059	CbGeAlD
Loxapine—DRD2—testis—prostate cancer	0.000951	0.00578	CbGeAlD
Loxapine—ADRA2C—testis—prostate cancer	0.000924	0.00562	CbGeAlD
Loxapine—SLC6A2—lymph node—prostate cancer	0.000756	0.0046	CbGeAlD
Loxapine—HRH1—testis—prostate cancer	0.000751	0.00456	CbGeAlD
Loxapine—ADRA2A—testis—prostate cancer	0.000737	0.00448	CbGeAlD
Loxapine—ADRA2C—lymph node—prostate cancer	0.00067	0.00407	CbGeAlD
Loxapine—HTR2A—testis—prostate cancer	0.000627	0.00381	CbGeAlD
Loxapine—Asenapine—ADRB2—prostate cancer	0.000592	0.0456	CrCbGaD
Loxapine—Clobazam—CYP2C18—prostate cancer	0.000573	0.0441	CrCbGaD
Loxapine—HRH1—lymph node—prostate cancer	0.000544	0.00331	CbGeAlD
Loxapine—ADRA2A—lymph node—prostate cancer	0.000535	0.00325	CbGeAlD
Loxapine—Azelastine—CYP3A5—prostate cancer	0.000485	0.0374	CrCbGaD
Loxapine—Azelastine—CYP2A6—prostate cancer	0.000469	0.0362	CrCbGaD
Loxapine—Thiothixene—SLC22A1—prostate cancer	0.000467	0.036	CrCbGaD
Loxapine—Azatadine—CYP3A4—prostate cancer	0.000422	0.0325	CrCbGaD
Loxapine—Trazodone—CYP3A5—prostate cancer	0.000403	0.031	CrCbGaD
Loxapine—Alprazolam—CYP3A5—prostate cancer	0.000377	0.0291	CrCbGaD
Loxapine—Diazepam—CYP2C18—prostate cancer	0.000334	0.0258	CrCbGaD
Loxapine—Azelastine—CYP2E1—prostate cancer	0.000333	0.0257	CrCbGaD
Loxapine—Azelastine—CYP2C19—prostate cancer	0.00033	0.0254	CrCbGaD
Loxapine—Azelastine—CYP1A1—prostate cancer	0.000329	0.0253	CrCbGaD
Loxapine—Chest pain—Etoposide—prostate cancer	0.000326	0.000715	CcSEcCtD
Loxapine—Orthostatic hypotension—Epirubicin—prostate cancer	0.000326	0.000714	CcSEcCtD
Loxapine—Fatigue—Mitoxantrone—prostate cancer	0.000324	0.00071	CcSEcCtD
Loxapine—Asenapine—CYP3A4—prostate cancer	0.000324	0.025	CrCbGaD
Loxapine—Vomiting—Goserelin—prostate cancer	0.000324	0.000709	CcSEcCtD
Loxapine—Alopecia—Docetaxel—prostate cancer	0.000323	0.000709	CcSEcCtD
Loxapine—Constipation—Mitoxantrone—prostate cancer	0.000322	0.000705	CcSEcCtD
Loxapine—Angiopathy—Capecitabine—prostate cancer	0.000322	0.000704	CcSEcCtD
Loxapine—Rash—Goserelin—prostate cancer	0.000321	0.000703	CcSEcCtD
Loxapine—Dermatitis—Goserelin—prostate cancer	0.000321	0.000703	CcSEcCtD
Loxapine—Vomiting—Conjugated Estrogens—prostate cancer	0.000321	0.000703	CcSEcCtD
Loxapine—Mediastinal disorder—Capecitabine—prostate cancer	0.000319	0.0007	CcSEcCtD
Loxapine—Headache—Goserelin—prostate cancer	0.000319	0.000699	CcSEcCtD
Loxapine—Rash—Conjugated Estrogens—prostate cancer	0.000318	0.000697	CcSEcCtD
Loxapine—Dermatitis—Conjugated Estrogens—prostate cancer	0.000318	0.000696	CcSEcCtD
Loxapine—Headache—Conjugated Estrogens—prostate cancer	0.000316	0.000692	CcSEcCtD
Loxapine—Confusional state—Etoposide—prostate cancer	0.000316	0.000691	CcSEcCtD
Loxapine—Alopecia—Capecitabine—prostate cancer	0.000313	0.000686	CcSEcCtD
Loxapine—Dysgeusia—Docetaxel—prostate cancer	0.000312	0.000684	CcSEcCtD
Loxapine—Feeling abnormal—Mitoxantrone—prostate cancer	0.00031	0.000679	CcSEcCtD
Loxapine—Dysphagia—Epirubicin—prostate cancer	0.000308	0.000676	CcSEcCtD
Loxapine—Thrombocytopenia—Etoposide—prostate cancer	0.000306	0.000671	CcSEcCtD
Loxapine—Muscle spasms—Docetaxel—prostate cancer	0.000306	0.000671	CcSEcCtD
Loxapine—Tachycardia—Etoposide—prostate cancer	0.000305	0.000669	CcSEcCtD
Loxapine—Nausea—Goserelin—prostate cancer	0.000303	0.000663	CcSEcCtD
Loxapine—Dysgeusia—Capecitabine—prostate cancer	0.000302	0.000662	CcSEcCtD
Loxapine—Orthostatic hypotension—Doxorubicin—prostate cancer	0.000302	0.000661	CcSEcCtD
Loxapine—Nausea—Conjugated Estrogens—prostate cancer	0.0003	0.000656	CcSEcCtD
Loxapine—Hypersensitivity—Estradiol—prostate cancer	0.000297	0.000652	CcSEcCtD
Loxapine—Muscle spasms—Capecitabine—prostate cancer	0.000297	0.00065	CcSEcCtD
Loxapine—Hypotension—Etoposide—prostate cancer	0.000292	0.000641	CcSEcCtD
Loxapine—Vision blurred—Capecitabine—prostate cancer	0.000291	0.000637	CcSEcCtD
Loxapine—Asthenia—Estradiol—prostate cancer	0.00029	0.000635	CcSEcCtD
Loxapine—Tremor—Capecitabine—prostate cancer	0.000289	0.000633	CcSEcCtD
Loxapine—Angiopathy—Prednisone—prostate cancer	0.000286	0.000627	CcSEcCtD
Loxapine—Syncope—Docetaxel—prostate cancer	0.000286	0.000626	CcSEcCtD
Loxapine—Pruritus—Estradiol—prostate cancer	0.000286	0.000626	CcSEcCtD
Loxapine—Dysphagia—Doxorubicin—prostate cancer	0.000285	0.000625	CcSEcCtD
Loxapine—Leukopenia—Docetaxel—prostate cancer	0.000285	0.000625	CcSEcCtD
Loxapine—Olanzapine—CYP2C19—prostate cancer	0.000284	0.0218	CrCbGaD
Loxapine—Photosensitivity reaction—Epirubicin—prostate cancer	0.000282	0.000617	CcSEcCtD
Loxapine—Paraesthesia—Etoposide—prostate cancer	0.000281	0.000616	CcSEcCtD
Loxapine—Weight increased—Epirubicin—prostate cancer	0.000281	0.000615	CcSEcCtD
Loxapine—Loss of consciousness—Docetaxel—prostate cancer	0.00028	0.000613	CcSEcCtD
Loxapine—Weight decreased—Epirubicin—prostate cancer	0.000279	0.000611	CcSEcCtD
Loxapine—Dyspnoea—Etoposide—prostate cancer	0.000279	0.000611	CcSEcCtD
Loxapine—Alopecia—Prednisone—prostate cancer	0.000279	0.000611	CcSEcCtD
Loxapine—Somnolence—Etoposide—prostate cancer	0.000278	0.000609	CcSEcCtD
Loxapine—Cough—Docetaxel—prostate cancer	0.000278	0.000609	CcSEcCtD
Loxapine—Hypersensitivity—Mitoxantrone—prostate cancer	0.000277	0.000607	CcSEcCtD
Loxapine—Syncope—Capecitabine—prostate cancer	0.000277	0.000606	CcSEcCtD
Loxapine—Leukopenia—Capecitabine—prostate cancer	0.000276	0.000605	CcSEcCtD
Loxapine—Convulsion—Docetaxel—prostate cancer	0.000276	0.000605	CcSEcCtD
Loxapine—Hypertension—Docetaxel—prostate cancer	0.000275	0.000603	CcSEcCtD
Loxapine—Drowsiness—Epirubicin—prostate cancer	0.000275	0.000602	CcSEcCtD
Loxapine—Clozapine—CYP1B1—prostate cancer	0.000273	0.021	CrCbGaD
Loxapine—Chest pain—Docetaxel—prostate cancer	0.000271	0.000594	CcSEcCtD
Loxapine—Loss of consciousness—Capecitabine—prostate cancer	0.000271	0.000594	CcSEcCtD
Loxapine—Renal failure—Epirubicin—prostate cancer	0.00027	0.000592	CcSEcCtD
Loxapine—Gastrointestinal disorder—Etoposide—prostate cancer	0.00027	0.000592	CcSEcCtD
Loxapine—Asthenia—Mitoxantrone—prostate cancer	0.00027	0.000591	CcSEcCtD
Loxapine—Fatigue—Etoposide—prostate cancer	0.00027	0.000591	CcSEcCtD
Loxapine—Cough—Capecitabine—prostate cancer	0.000269	0.00059	CcSEcCtD
Loxapine—Jaundice—Epirubicin—prostate cancer	0.000268	0.000587	CcSEcCtD
Loxapine—Constipation—Etoposide—prostate cancer	0.000268	0.000586	CcSEcCtD
Loxapine—Dizziness—Estradiol—prostate cancer	0.000267	0.000585	CcSEcCtD
Loxapine—Hypertension—Capecitabine—prostate cancer	0.000266	0.000583	CcSEcCtD
Loxapine—Dry mouth—Docetaxel—prostate cancer	0.000265	0.000581	CcSEcCtD
Loxapine—Chest pain—Capecitabine—prostate cancer	0.000263	0.000575	CcSEcCtD
Loxapine—Confusional state—Docetaxel—prostate cancer	0.000262	0.000574	CcSEcCtD
Loxapine—Photosensitivity reaction—Doxorubicin—prostate cancer	0.00026	0.000571	CcSEcCtD
Loxapine—Oedema—Docetaxel—prostate cancer	0.00026	0.00057	CcSEcCtD
Loxapine—Weight increased—Doxorubicin—prostate cancer	0.00026	0.000569	CcSEcCtD
Loxapine—Vision blurred—Prednisone—prostate cancer	0.000259	0.000567	CcSEcCtD
Loxapine—Weight decreased—Doxorubicin—prostate cancer	0.000258	0.000566	CcSEcCtD
Loxapine—Feeling abnormal—Etoposide—prostate cancer	0.000258	0.000565	CcSEcCtD
Loxapine—Dry mouth—Capecitabine—prostate cancer	0.000257	0.000563	CcSEcCtD
Loxapine—Clobazam—CYP2C19—prostate cancer	0.000257	0.0198	CrCbGaD
Loxapine—Vomiting—Estradiol—prostate cancer	0.000257	0.000562	CcSEcCtD
Loxapine—Agranulocytosis—Epirubicin—prostate cancer	0.000257	0.000562	CcSEcCtD
Loxapine—Shock—Docetaxel—prostate cancer	0.000256	0.00056	CcSEcCtD
Loxapine—Nervous system disorder—Docetaxel—prostate cancer	0.000255	0.000559	CcSEcCtD
Loxapine—Thrombocytopenia—Docetaxel—prostate cancer	0.000255	0.000558	CcSEcCtD
Loxapine—Rash—Estradiol—prostate cancer	0.000255	0.000558	CcSEcCtD
Loxapine—Drowsiness—Doxorubicin—prostate cancer	0.000254	0.000557	CcSEcCtD
Loxapine—Dermatitis—Estradiol—prostate cancer	0.000254	0.000557	CcSEcCtD
Loxapine—Confusional state—Capecitabine—prostate cancer	0.000254	0.000556	CcSEcCtD
Loxapine—Tachycardia—Docetaxel—prostate cancer	0.000254	0.000556	CcSEcCtD
Loxapine—Headache—Estradiol—prostate cancer	0.000253	0.000554	CcSEcCtD
Loxapine—Quetiapine—CYP3A5—prostate cancer	0.000253	0.0195	CrCbGaD
Loxapine—Agitation—Prednisone—prostate cancer	0.000253	0.000553	CcSEcCtD
Loxapine—Oedema—Capecitabine—prostate cancer	0.000252	0.000552	CcSEcCtD
Loxapine—Renal failure—Doxorubicin—prostate cancer	0.00025	0.000548	CcSEcCtD
Loxapine—Jaundice—Doxorubicin—prostate cancer	0.000248	0.000543	CcSEcCtD
Loxapine—Shock—Capecitabine—prostate cancer	0.000248	0.000543	CcSEcCtD
Loxapine—Nervous system disorder—Capecitabine—prostate cancer	0.000247	0.000541	CcSEcCtD
Loxapine—Hepatitis—Epirubicin—prostate cancer	0.000247	0.000541	CcSEcCtD
Loxapine—Thrombocytopenia—Capecitabine—prostate cancer	0.000247	0.00054	CcSEcCtD
Loxapine—Syncope—Prednisone—prostate cancer	0.000246	0.00054	CcSEcCtD
Loxapine—Tachycardia—Capecitabine—prostate cancer	0.000246	0.000538	CcSEcCtD
Loxapine—Hypoaesthesia—Epirubicin—prostate cancer	0.000246	0.000538	CcSEcCtD
Loxapine—Hypotension—Docetaxel—prostate cancer	0.000243	0.000532	CcSEcCtD
Loxapine—Loss of consciousness—Prednisone—prostate cancer	0.000242	0.000529	CcSEcCtD
Loxapine—Nausea—Estradiol—prostate cancer	0.00024	0.000525	CcSEcCtD
Loxapine—Vomiting—Mitoxantrone—prostate cancer	0.000239	0.000524	CcSEcCtD
Loxapine—Convulsion—Prednisone—prostate cancer	0.000238	0.000522	CcSEcCtD
Loxapine—Agranulocytosis—Doxorubicin—prostate cancer	0.000237	0.00052	CcSEcCtD
Loxapine—Hypertension—Prednisone—prostate cancer	0.000237	0.00052	CcSEcCtD
Loxapine—Rash—Mitoxantrone—prostate cancer	0.000237	0.00052	CcSEcCtD
Loxapine—Dermatitis—Mitoxantrone—prostate cancer	0.000237	0.000519	CcSEcCtD
Loxapine—Headache—Mitoxantrone—prostate cancer	0.000236	0.000516	CcSEcCtD
Loxapine—Hypotension—Capecitabine—prostate cancer	0.000235	0.000515	CcSEcCtD
Loxapine—Insomnia—Docetaxel—prostate cancer	0.000235	0.000515	CcSEcCtD
Loxapine—Paraesthesia—Docetaxel—prostate cancer	0.000234	0.000512	CcSEcCtD
Loxapine—Dyspnoea—Docetaxel—prostate cancer	0.000232	0.000508	CcSEcCtD
Loxapine—Somnolence—Docetaxel—prostate cancer	0.000231	0.000506	CcSEcCtD
Loxapine—Hypersensitivity—Etoposide—prostate cancer	0.000231	0.000505	CcSEcCtD
Loxapine—Hepatitis—Doxorubicin—prostate cancer	0.000228	0.0005	CcSEcCtD
Loxapine—Insomnia—Capecitabine—prostate cancer	0.000228	0.000499	CcSEcCtD
Loxapine—Hypoaesthesia—Doxorubicin—prostate cancer	0.000227	0.000498	CcSEcCtD
Loxapine—Paraesthesia—Capecitabine—prostate cancer	0.000226	0.000495	CcSEcCtD
Loxapine—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000225	0.000492	CcSEcCtD
Loxapine—Asthenia—Etoposide—prostate cancer	0.000224	0.000492	CcSEcCtD
Loxapine—Dyspnoea—Capecitabine—prostate cancer	0.000224	0.000492	CcSEcCtD
Loxapine—Oedema—Prednisone—prostate cancer	0.000224	0.000491	CcSEcCtD
Loxapine—Fatigue—Docetaxel—prostate cancer	0.000224	0.000491	CcSEcCtD
Loxapine—Angiopathy—Epirubicin—prostate cancer	0.000224	0.000491	CcSEcCtD
Loxapine—Nausea—Mitoxantrone—prostate cancer	0.000223	0.000489	CcSEcCtD
Loxapine—Mediastinal disorder—Epirubicin—prostate cancer	0.000222	0.000487	CcSEcCtD
Loxapine—Constipation—Docetaxel—prostate cancer	0.000222	0.000487	CcSEcCtD
Loxapine—Pruritus—Etoposide—prostate cancer	0.000221	0.000485	CcSEcCtD
Loxapine—Shock—Prednisone—prostate cancer	0.000221	0.000483	CcSEcCtD
Loxapine—Diazepam—CYP3A5—prostate cancer	0.00022	0.017	CrCbGaD
Loxapine—Nervous system disorder—Prednisone—prostate cancer	0.00022	0.000482	CcSEcCtD
Loxapine—Tachycardia—Prednisone—prostate cancer	0.000219	0.000479	CcSEcCtD
Loxapine—Alopecia—Epirubicin—prostate cancer	0.000218	0.000478	CcSEcCtD
Loxapine—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000217	0.000476	CcSEcCtD
Loxapine—Fatigue—Capecitabine—prostate cancer	0.000217	0.000476	CcSEcCtD
Loxapine—Constipation—Capecitabine—prostate cancer	0.000215	0.000472	CcSEcCtD
Loxapine—Feeling abnormal—Docetaxel—prostate cancer	0.000214	0.000469	CcSEcCtD
Loxapine—Tension—Epirubicin—prostate cancer	0.000211	0.000462	CcSEcCtD
Loxapine—Clozapine—CYP2A6—prostate cancer	0.00021	0.0162	CrCbGaD
Loxapine—Dysgeusia—Epirubicin—prostate cancer	0.00021	0.000461	CcSEcCtD
Loxapine—Azelastine—CYP3A4—prostate cancer	0.00021	0.0162	CrCbGaD
Loxapine—Feeling abnormal—Capecitabine—prostate cancer	0.000207	0.000454	CcSEcCtD
Loxapine—Angiopathy—Doxorubicin—prostate cancer	0.000207	0.000454	CcSEcCtD
Loxapine—Dizziness—Etoposide—prostate cancer	0.000207	0.000453	CcSEcCtD
Loxapine—Muscle spasms—Epirubicin—prostate cancer	0.000207	0.000453	CcSEcCtD
Loxapine—Mediastinal disorder—Doxorubicin—prostate cancer	0.000206	0.000451	CcSEcCtD
Loxapine—Insomnia—Prednisone—prostate cancer	0.000203	0.000444	CcSEcCtD
Loxapine—Vision blurred—Epirubicin—prostate cancer	0.000203	0.000444	CcSEcCtD
Loxapine—Alopecia—Doxorubicin—prostate cancer	0.000202	0.000442	CcSEcCtD
Loxapine—Paraesthesia—Prednisone—prostate cancer	0.000201	0.000441	CcSEcCtD
Loxapine—Vomiting—Etoposide—prostate cancer	0.000199	0.000436	CcSEcCtD
Loxapine—Agitation—Epirubicin—prostate cancer	0.000197	0.000433	CcSEcCtD
Loxapine—Rash—Etoposide—prostate cancer	0.000197	0.000432	CcSEcCtD
Loxapine—Dermatitis—Etoposide—prostate cancer	0.000197	0.000432	CcSEcCtD
Loxapine—Headache—Etoposide—prostate cancer	0.000196	0.000429	CcSEcCtD
Loxapine—Tension—Doxorubicin—prostate cancer	0.000195	0.000427	CcSEcCtD
Loxapine—Dysgeusia—Doxorubicin—prostate cancer	0.000195	0.000427	CcSEcCtD
Loxapine—Fatigue—Prednisone—prostate cancer	0.000193	0.000424	CcSEcCtD
Loxapine—Chlordiazepoxide—CYP3A4—prostate cancer	0.000193	0.0149	CrCbGaD
Loxapine—Syncope—Epirubicin—prostate cancer	0.000193	0.000422	CcSEcCtD
Loxapine—Leukopenia—Epirubicin—prostate cancer	0.000192	0.000421	CcSEcCtD
Loxapine—Constipation—Prednisone—prostate cancer	0.000192	0.00042	CcSEcCtD
Loxapine—Hypersensitivity—Docetaxel—prostate cancer	0.000192	0.00042	CcSEcCtD
Loxapine—Muscle spasms—Doxorubicin—prostate cancer	0.000191	0.000419	CcSEcCtD
Loxapine—Loss of consciousness—Epirubicin—prostate cancer	0.000189	0.000414	CcSEcCtD
Loxapine—Cough—Epirubicin—prostate cancer	0.000188	0.000411	CcSEcCtD
Loxapine—Vision blurred—Doxorubicin—prostate cancer	0.000187	0.000411	CcSEcCtD
Loxapine—Asthenia—Docetaxel—prostate cancer	0.000187	0.000409	CcSEcCtD
Loxapine—Convulsion—Epirubicin—prostate cancer	0.000186	0.000408	CcSEcCtD
Loxapine—Nausea—Etoposide—prostate cancer	0.000186	0.000407	CcSEcCtD
Loxapine—Hypertension—Epirubicin—prostate cancer	0.000186	0.000406	CcSEcCtD
Loxapine—Hypersensitivity—Capecitabine—prostate cancer	0.000185	0.000406	CcSEcCtD
Loxapine—Feeling abnormal—Prednisone—prostate cancer	0.000185	0.000405	CcSEcCtD
Loxapine—Pruritus—Docetaxel—prostate cancer	0.000184	0.000403	CcSEcCtD
Loxapine—Chest pain—Epirubicin—prostate cancer	0.000183	0.000401	CcSEcCtD
Loxapine—Agitation—Doxorubicin—prostate cancer	0.000183	0.0004	CcSEcCtD
Loxapine—Asthenia—Capecitabine—prostate cancer	0.000181	0.000396	CcSEcCtD
Loxapine—Temazepam—CYP2C19—prostate cancer	0.00018	0.0139	CrCbGaD
Loxapine—Olanzapine—CYP3A4—prostate cancer	0.00018	0.0139	CrCbGaD
Loxapine—Dry mouth—Epirubicin—prostate cancer	0.000179	0.000392	CcSEcCtD
Loxapine—Syncope—Doxorubicin—prostate cancer	0.000178	0.000391	CcSEcCtD
Loxapine—Pruritus—Capecitabine—prostate cancer	0.000178	0.00039	CcSEcCtD
Loxapine—Leukopenia—Doxorubicin—prostate cancer	0.000178	0.00039	CcSEcCtD
Loxapine—Confusional state—Epirubicin—prostate cancer	0.000177	0.000387	CcSEcCtD
Loxapine—Oedema—Epirubicin—prostate cancer	0.000175	0.000384	CcSEcCtD
Loxapine—Loss of consciousness—Doxorubicin—prostate cancer	0.000175	0.000383	CcSEcCtD
Loxapine—Trazodone—CYP3A4—prostate cancer	0.000174	0.0134	CrCbGaD
Loxapine—Cough—Doxorubicin—prostate cancer	0.000174	0.00038	CcSEcCtD
Loxapine—Shock—Epirubicin—prostate cancer	0.000173	0.000378	CcSEcCtD
Loxapine—Convulsion—Doxorubicin—prostate cancer	0.000172	0.000377	CcSEcCtD
Loxapine—Quetiapine—CYP2C19—prostate cancer	0.000172	0.0133	CrCbGaD
Loxapine—Nervous system disorder—Epirubicin—prostate cancer	0.000172	0.000377	CcSEcCtD
Loxapine—Dizziness—Docetaxel—prostate cancer	0.000172	0.000377	CcSEcCtD
Loxapine—Thrombocytopenia—Epirubicin—prostate cancer	0.000172	0.000376	CcSEcCtD
Loxapine—Hypertension—Doxorubicin—prostate cancer	0.000172	0.000376	CcSEcCtD
Loxapine—Tachycardia—Epirubicin—prostate cancer	0.000171	0.000375	CcSEcCtD
Loxapine—Chest pain—Doxorubicin—prostate cancer	0.000169	0.000371	CcSEcCtD
Loxapine—Dizziness—Capecitabine—prostate cancer	0.000166	0.000365	CcSEcCtD
Loxapine—Dry mouth—Doxorubicin—prostate cancer	0.000166	0.000363	CcSEcCtD
Loxapine—Vomiting—Docetaxel—prostate cancer	0.000165	0.000362	CcSEcCtD
Loxapine—Hypersensitivity—Prednisone—prostate cancer	0.000165	0.000362	CcSEcCtD
Loxapine—Rash—Docetaxel—prostate cancer	0.000164	0.000359	CcSEcCtD
Loxapine—Hypotension—Epirubicin—prostate cancer	0.000164	0.000359	CcSEcCtD
Loxapine—Dermatitis—Docetaxel—prostate cancer	0.000164	0.000359	CcSEcCtD
Loxapine—Confusional state—Doxorubicin—prostate cancer	0.000164	0.000358	CcSEcCtD
Loxapine—Alprazolam—CYP3A4—prostate cancer	0.000163	0.0126	CrCbGaD
Loxapine—Clobazam—CYP3A4—prostate cancer	0.000163	0.0126	CrCbGaD
Loxapine—Headache—Docetaxel—prostate cancer	0.000163	0.000357	CcSEcCtD
Loxapine—Oedema—Doxorubicin—prostate cancer	0.000162	0.000356	CcSEcCtD
Loxapine—Asthenia—Prednisone—prostate cancer	0.000161	0.000352	CcSEcCtD
Loxapine—Vomiting—Capecitabine—prostate cancer	0.00016	0.000351	CcSEcCtD
Loxapine—Shock—Doxorubicin—prostate cancer	0.00016	0.00035	CcSEcCtD
Loxapine—Nervous system disorder—Doxorubicin—prostate cancer	0.000159	0.000349	CcSEcCtD
Loxapine—Thrombocytopenia—Doxorubicin—prostate cancer	0.000159	0.000348	CcSEcCtD
Loxapine—Rash—Capecitabine—prostate cancer	0.000159	0.000348	CcSEcCtD
Loxapine—Pruritus—Prednisone—prostate cancer	0.000159	0.000348	CcSEcCtD
Loxapine—Insomnia—Epirubicin—prostate cancer	0.000159	0.000348	CcSEcCtD
Loxapine—Dermatitis—Capecitabine—prostate cancer	0.000159	0.000347	CcSEcCtD
Loxapine—Tachycardia—Doxorubicin—prostate cancer	0.000158	0.000347	CcSEcCtD
Loxapine—Headache—Capecitabine—prostate cancer	0.000158	0.000346	CcSEcCtD
Loxapine—Paraesthesia—Epirubicin—prostate cancer	0.000157	0.000345	CcSEcCtD
Loxapine—Dyspnoea—Epirubicin—prostate cancer	0.000156	0.000343	CcSEcCtD
Loxapine—Prochlorperazine—CYP3A4—prostate cancer	0.000156	0.012	CrCbGaD
Loxapine—Somnolence—Epirubicin—prostate cancer	0.000156	0.000342	CcSEcCtD
Loxapine—Nausea—Docetaxel—prostate cancer	0.000154	0.000338	CcSEcCtD
Loxapine—Hypotension—Doxorubicin—prostate cancer	0.000152	0.000332	CcSEcCtD
Loxapine—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000151	0.000332	CcSEcCtD
Loxapine—Diazepam—CYP2E1—prostate cancer	0.000151	0.0117	CrCbGaD
Loxapine—Fatigue—Epirubicin—prostate cancer	0.000151	0.000331	CcSEcCtD
Loxapine—Constipation—Epirubicin—prostate cancer	0.00015	0.000329	CcSEcCtD
Loxapine—Diazepam—CYP2C19—prostate cancer	0.00015	0.0115	CrCbGaD
Loxapine—Nausea—Capecitabine—prostate cancer	0.00015	0.000328	CcSEcCtD
Loxapine—Clozapine—CYP2E1—prostate cancer	0.000149	0.0115	CrCbGaD
Loxapine—Dizziness—Prednisone—prostate cancer	0.000148	0.000325	CcSEcCtD
Loxapine—Clozapine—CYP2C19—prostate cancer	0.000148	0.0114	CrCbGaD
Loxapine—Clozapine—CYP1A1—prostate cancer	0.000147	0.0114	CrCbGaD
Loxapine—Insomnia—Doxorubicin—prostate cancer	0.000147	0.000322	CcSEcCtD
Loxapine—Paraesthesia—Doxorubicin—prostate cancer	0.000146	0.000319	CcSEcCtD
Loxapine—Dyspnoea—Doxorubicin—prostate cancer	0.000145	0.000317	CcSEcCtD
Loxapine—Feeling abnormal—Epirubicin—prostate cancer	0.000145	0.000317	CcSEcCtD
Loxapine—Somnolence—Doxorubicin—prostate cancer	0.000144	0.000316	CcSEcCtD
Loxapine—Vomiting—Prednisone—prostate cancer	0.000143	0.000312	CcSEcCtD
Loxapine—Rash—Prednisone—prostate cancer	0.000141	0.00031	CcSEcCtD
Loxapine—Dermatitis—Prednisone—prostate cancer	0.000141	0.000309	CcSEcCtD
Loxapine—Headache—Prednisone—prostate cancer	0.00014	0.000308	CcSEcCtD
Loxapine—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.00014	0.000307	CcSEcCtD
Loxapine—Fatigue—Doxorubicin—prostate cancer	0.00014	0.000307	CcSEcCtD
Loxapine—Constipation—Doxorubicin—prostate cancer	0.000139	0.000304	CcSEcCtD
Loxapine—Feeling abnormal—Doxorubicin—prostate cancer	0.000134	0.000293	CcSEcCtD
Loxapine—Nausea—Prednisone—prostate cancer	0.000133	0.000292	CcSEcCtD
Loxapine—Hypersensitivity—Epirubicin—prostate cancer	0.000129	0.000283	CcSEcCtD
Loxapine—Prazepam—CYP3A4—prostate cancer	0.000129	0.00991	CrCbGaD
Loxapine—Asthenia—Epirubicin—prostate cancer	0.000126	0.000276	CcSEcCtD
Loxapine—Pruritus—Epirubicin—prostate cancer	0.000124	0.000272	CcSEcCtD
Loxapine—Hypersensitivity—Doxorubicin—prostate cancer	0.00012	0.000262	CcSEcCtD
Loxapine—Asthenia—Doxorubicin—prostate cancer	0.000116	0.000255	CcSEcCtD
Loxapine—Dizziness—Epirubicin—prostate cancer	0.000116	0.000254	CcSEcCtD
Loxapine—Pruritus—Doxorubicin—prostate cancer	0.000115	0.000252	CcSEcCtD
Loxapine—Temazepam—CYP3A4—prostate cancer	0.000115	0.00884	CrCbGaD
Loxapine—Vomiting—Epirubicin—prostate cancer	0.000112	0.000244	CcSEcCtD
Loxapine—Rash—Epirubicin—prostate cancer	0.000111	0.000242	CcSEcCtD
Loxapine—Dermatitis—Epirubicin—prostate cancer	0.00011	0.000242	CcSEcCtD
Loxapine—Headache—Epirubicin—prostate cancer	0.00011	0.000241	CcSEcCtD
Loxapine—Quetiapine—CYP3A4—prostate cancer	0.000109	0.00843	CrCbGaD
Loxapine—Dizziness—Doxorubicin—prostate cancer	0.000107	0.000235	CcSEcCtD
Loxapine—Nausea—Epirubicin—prostate cancer	0.000104	0.000228	CcSEcCtD
Loxapine—Vomiting—Doxorubicin—prostate cancer	0.000103	0.000226	CcSEcCtD
Loxapine—Rash—Doxorubicin—prostate cancer	0.000102	0.000224	CcSEcCtD
Loxapine—Dermatitis—Doxorubicin—prostate cancer	0.000102	0.000224	CcSEcCtD
Loxapine—Headache—Doxorubicin—prostate cancer	0.000102	0.000223	CcSEcCtD
Loxapine—Nausea—Doxorubicin—prostate cancer	9.64e-05	0.000211	CcSEcCtD
Loxapine—Diazepam—CYP3A4—prostate cancer	9.53e-05	0.00734	CrCbGaD
Loxapine—Clozapine—CYP3A4—prostate cancer	9.41e-05	0.00725	CrCbGaD
Loxapine—HTR1A—Signaling Pathways—VEGFA—prostate cancer	3.99e-06	1.09e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CASP3—prostate cancer	3.99e-06	1.09e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL2—prostate cancer	3.98e-06	1.09e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CTNNB1—prostate cancer	3.98e-06	1.09e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CASP3—prostate cancer	3.98e-06	1.09e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL2—prostate cancer	3.97e-06	1.08e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—PIK3CA—prostate cancer	3.97e-06	1.08e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—VEGFA—prostate cancer	3.97e-06	1.08e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—SRC—prostate cancer	3.96e-06	1.08e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—IL6—prostate cancer	3.96e-06	1.08e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—EP300—prostate cancer	3.96e-06	1.08e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—TP53—prostate cancer	3.96e-06	1.08e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CCND1—prostate cancer	3.95e-06	1.08e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—IL6—prostate cancer	3.95e-06	1.08e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—STAT3—prostate cancer	3.95e-06	1.08e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CCND1—prostate cancer	3.95e-06	1.08e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—KRAS—prostate cancer	3.94e-06	1.08e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CCND1—prostate cancer	3.93e-06	1.07e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—STAT3—prostate cancer	3.93e-06	1.07e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CCND1—prostate cancer	3.92e-06	1.07e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CTNNB1—prostate cancer	3.92e-06	1.07e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CTNNB1—prostate cancer	3.91e-06	1.07e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—SRC—prostate cancer	3.9e-06	1.07e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MMP9—prostate cancer	3.9e-06	1.07e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CTNNB1—prostate cancer	3.89e-06	1.06e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—TP53—prostate cancer	3.89e-06	1.06e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—KRAS—prostate cancer	3.89e-06	1.06e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CDKN1A—prostate cancer	3.89e-06	1.06e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CCND1—prostate cancer	3.88e-06	1.06e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CTNNB1—prostate cancer	3.88e-06	1.06e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PTEN—prostate cancer	3.88e-06	1.06e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CCND1—prostate cancer	3.87e-06	1.06e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	3.86e-06	1.05e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—VEGFA—prostate cancer	3.86e-06	1.05e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CTNNB1—prostate cancer	3.84e-06	1.05e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TP53—prostate cancer	3.84e-06	1.05e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MMP9—prostate cancer	3.84e-06	1.05e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MYC—prostate cancer	3.84e-06	1.05e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	3.83e-06	1.05e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MMP9—prostate cancer	3.83e-06	1.05e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TGFB1—prostate cancer	3.83e-06	1.05e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CDKN1A—prostate cancer	3.83e-06	1.04e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—STAT3—prostate cancer	3.82e-06	1.04e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MMP9—prostate cancer	3.82e-06	1.04e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CDKN1A—prostate cancer	3.82e-06	1.04e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PTEN—prostate cancer	3.82e-06	1.04e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PTEN—prostate cancer	3.81e-06	1.04e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MMP9—prostate cancer	3.81e-06	1.04e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CDKN1A—prostate cancer	3.8e-06	1.04e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—PIK3CA—prostate cancer	3.8e-06	1.04e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MYC—prostate cancer	3.8e-06	1.04e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	3.8e-06	1.04e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PTEN—prostate cancer	3.8e-06	1.04e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TGFB1—prostate cancer	3.79e-06	1.04e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CDKN1A—prostate cancer	3.79e-06	1.04e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—AKT1—prostate cancer	3.78e-06	1.03e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PTEN—prostate cancer	3.78e-06	1.03e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	3.77e-06	1.03e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MMP9—prostate cancer	3.77e-06	1.03e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—STAT3—prostate cancer	3.76e-06	1.03e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MMP9—prostate cancer	3.76e-06	1.03e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CDKN1A—prostate cancer	3.76e-06	1.03e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—EGFR—prostate cancer	3.75e-06	1.03e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PTEN—prostate cancer	3.75e-06	1.02e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	3.75e-06	1.02e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PTEN—prostate cancer	3.74e-06	1.02e-05	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	3.73e-06	1.02e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—IL6—prostate cancer	3.73e-06	1.02e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—IL6—prostate cancer	3.72e-06	1.02e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—AKT1—prostate cancer	3.72e-06	1.02e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—EGFR—prostate cancer	3.72e-06	1.02e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—AKT1—prostate cancer	3.72e-06	1.01e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—AKT1—prostate cancer	3.7e-06	1.01e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IL6—prostate cancer	3.7e-06	1.01e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—EP300—prostate cancer	3.7e-06	1.01e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CASP3—prostate cancer	3.7e-06	1.01e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—AKT1—prostate cancer	3.69e-06	1.01e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL2—prostate cancer	3.69e-06	1.01e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TP53—prostate cancer	3.68e-06	1.01e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—IL6—prostate cancer	3.67e-06	1e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MYC—prostate cancer	3.67e-06	1e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TGFB1—prostate cancer	3.66e-06	1e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—AKT1—prostate cancer	3.66e-06	9.99e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MYC—prostate cancer	3.65e-06	9.98e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	3.65e-06	9.96e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TGFB1—prostate cancer	3.64e-06	9.95e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—EP300—prostate cancer	3.64e-06	9.94e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—EP300—prostate cancer	3.63e-06	9.92e-06	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—PIK3CA—prostate cancer	3.62e-06	9.9e-06	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL6—prostate cancer	3.62e-06	9.9e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—EP300—prostate cancer	3.62e-06	9.89e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—EP300—prostate cancer	3.61e-06	9.86e-06	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—PIK3CA—prostate cancer	3.61e-06	9.85e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCND1—prostate cancer	3.6e-06	9.83e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—SRC—prostate cancer	3.6e-06	9.83e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—EGFR—prostate cancer	3.59e-06	9.81e-06	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—PIK3CA—prostate cancer	3.58e-06	9.77e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—EP300—prostate cancer	3.57e-06	9.76e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—EGFR—prostate cancer	3.57e-06	9.76e-06	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL6—prostate cancer	3.56e-06	9.74e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—EP300—prostate cancer	3.56e-06	9.74e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	3.56e-06	9.73e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MYC—prostate cancer	3.55e-06	9.7e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—KRAS—prostate cancer	3.55e-06	9.69e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TGFB1—prostate cancer	3.54e-06	9.68e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—SRC—prostate cancer	3.54e-06	9.67e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—SRC—prostate cancer	3.53e-06	9.65e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—SRC—prostate cancer	3.52e-06	9.62e-06	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL6—prostate cancer	3.52e-06	9.61e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—KRAS—prostate cancer	3.51e-06	9.6e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—SRC—prostate cancer	3.51e-06	9.59e-06	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TP53—prostate cancer	3.51e-06	9.58e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—VEGFA—prostate cancer	3.5e-06	9.57e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MYC—prostate cancer	3.5e-06	9.55e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MMP9—prostate cancer	3.49e-06	9.54e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	3.49e-06	9.53e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	3.48e-06	9.51e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—SRC—prostate cancer	3.48e-06	9.49e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—EGFR—prostate cancer	3.47e-06	9.49e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PTEN—prostate cancer	3.47e-06	9.49e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—STAT3—prostate cancer	3.47e-06	9.48e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—SRC—prostate cancer	3.47e-06	9.47e-06	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TP53—prostate cancer	3.46e-06	9.45e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—VEGFA—prostate cancer	3.45e-06	9.42e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—VEGFA—prostate cancer	3.44e-06	9.4e-06	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—AKT1—prostate cancer	3.44e-06	9.4e-06	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—AKT1—prostate cancer	3.44e-06	9.39e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—VEGFA—prostate cancer	3.43e-06	9.37e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—EGFR—prostate cancer	3.42e-06	9.34e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—VEGFA—prostate cancer	3.42e-06	9.34e-06	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—AKT1—prostate cancer	3.41e-06	9.32e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—STAT3—prostate cancer	3.41e-06	9.32e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—STAT3—prostate cancer	3.41e-06	9.3e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—STAT3—prostate cancer	3.39e-06	9.27e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—KRAS—prostate cancer	3.39e-06	9.27e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	3.39e-06	9.25e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—VEGFA—prostate cancer	3.38e-06	9.25e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—STAT3—prostate cancer	3.38e-06	9.24e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	3.38e-06	9.22e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—KRAS—prostate cancer	3.37e-06	9.22e-06	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL6—prostate cancer	3.37e-06	9.2e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—STAT3—prostate cancer	3.35e-06	9.16e-06	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—AKT1—prostate cancer	3.34e-06	9.13e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—STAT3—prostate cancer	3.34e-06	9.13e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—EP300—prostate cancer	3.31e-06	9.05e-06	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—AKT1—prostate cancer	3.29e-06	8.98e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—KRAS—prostate cancer	3.28e-06	8.97e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	3.26e-06	8.9e-06	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—AKT1—prostate cancer	3.24e-06	8.86e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—KRAS—prostate cancer	3.23e-06	8.83e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—PIK3CA—prostate cancer	3.23e-06	8.82e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MYC—prostate cancer	3.22e-06	8.81e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—SRC—prostate cancer	3.22e-06	8.8e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TGFB1—prostate cancer	3.22e-06	8.78e-06	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL6—prostate cancer	3.21e-06	8.77e-06	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—PIK3CA—prostate cancer	3.19e-06	8.72e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MYC—prostate cancer	3.17e-06	8.66e-06	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL6—prostate cancer	3.17e-06	8.65e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MYC—prostate cancer	3.16e-06	8.65e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TGFB1—prostate cancer	3.16e-06	8.64e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TGFB1—prostate cancer	3.16e-06	8.62e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MYC—prostate cancer	3.15e-06	8.62e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—EGFR—prostate cancer	3.15e-06	8.61e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TP53—prostate cancer	3.15e-06	8.61e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TGFB1—prostate cancer	3.15e-06	8.6e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MYC—prostate cancer	3.14e-06	8.59e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TGFB1—prostate cancer	3.14e-06	8.57e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	3.14e-06	8.57e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TP53—prostate cancer	3.12e-06	8.53e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—PIK3CA—prostate cancer	3.12e-06	8.51e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MYC—prostate cancer	3.11e-06	8.51e-06	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—AKT1—prostate cancer	3.11e-06	8.49e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TGFB1—prostate cancer	3.11e-06	8.49e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MYC—prostate cancer	3.11e-06	8.48e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—STAT3—prostate cancer	3.11e-06	8.48e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—EGFR—prostate cancer	3.1e-06	8.47e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—PIK3CA—prostate cancer	3.1e-06	8.47e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	3.1e-06	8.46e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—EGFR—prostate cancer	3.1e-06	8.46e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—EGFR—prostate cancer	3.09e-06	8.43e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—EGFR—prostate cancer	3.08e-06	8.4e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—EGFR—prostate cancer	3.05e-06	8.32e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—EGFR—prostate cancer	3.04e-06	8.3e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—PIK3CA—prostate cancer	3.02e-06	8.24e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TP53—prostate cancer	3.01e-06	8.24e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TP53—prostate cancer	3e-06	8.19e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—KRAS—prostate cancer	2.98e-06	8.14e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	2.97e-06	8.11e-06	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—AKT1—prostate cancer	2.96e-06	8.09e-06	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—AKT1—prostate cancer	2.95e-06	8.05e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—KRAS—prostate cancer	2.93e-06	8.01e-06	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PIK3CA—prostate cancer	2.93e-06	8e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—KRAS—prostate cancer	2.92e-06	7.99e-06	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—AKT1—prostate cancer	2.92e-06	7.98e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TP53—prostate cancer	2.92e-06	7.97e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—KRAS—prostate cancer	2.91e-06	7.96e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—KRAS—prostate cancer	2.91e-06	7.94e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MYC—prostate cancer	2.89e-06	7.88e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL6—prostate cancer	2.89e-06	7.88e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	2.88e-06	7.86e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—KRAS—prostate cancer	2.88e-06	7.86e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TP53—prostate cancer	2.87e-06	7.84e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—KRAS—prostate cancer	2.87e-06	7.84e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL6—prostate cancer	2.86e-06	7.81e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—EGFR—prostate cancer	2.82e-06	7.71e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL6—prostate cancer	2.76e-06	7.54e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL6—prostate cancer	2.75e-06	7.5e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PIK3CA—prostate cancer	2.74e-06	7.48e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	2.69e-06	7.36e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PIK3CA—prostate cancer	2.69e-06	7.34e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PIK3CA—prostate cancer	2.68e-06	7.32e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL6—prostate cancer	2.67e-06	7.3e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PIK3CA—prostate cancer	2.67e-06	7.29e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—KRAS—prostate cancer	2.67e-06	7.28e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—AKT1—prostate cancer	2.66e-06	7.27e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TP53—prostate cancer	2.65e-06	7.23e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PIK3CA—prostate cancer	2.64e-06	7.22e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—AKT1—prostate cancer	2.64e-06	7.2e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	2.64e-06	7.2e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL6—prostate cancer	2.63e-06	7.18e-06	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—AKT1—prostate cancer	2.61e-06	7.12e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TP53—prostate cancer	2.6e-06	7.12e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TP53—prostate cancer	2.6e-06	7.1e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TP53—prostate cancer	2.59e-06	7.08e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TP53—prostate cancer	2.58e-06	7.05e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TP53—prostate cancer	2.56e-06	6.99e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TP53—prostate cancer	2.55e-06	6.97e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—AKT1—prostate cancer	2.55e-06	6.96e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—AKT1—prostate cancer	2.53e-06	6.92e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—AKT1—prostate cancer	2.46e-06	6.73e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	2.45e-06	6.69e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—AKT1—prostate cancer	2.42e-06	6.62e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL6—prostate cancer	2.42e-06	6.62e-06	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—AKT1—prostate cancer	2.39e-06	6.54e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL6—prostate cancer	2.38e-06	6.51e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL6—prostate cancer	2.38e-06	6.5e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL6—prostate cancer	2.37e-06	6.48e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TP53—prostate cancer	2.37e-06	6.47e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL6—prostate cancer	2.36e-06	6.46e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL6—prostate cancer	2.34e-06	6.39e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL6—prostate cancer	2.33e-06	6.38e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—AKT1—prostate cancer	2.24e-06	6.11e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—AKT1—prostate cancer	2.2e-06	6.01e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—AKT1—prostate cancer	2.19e-06	6e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—AKT1—prostate cancer	2.19e-06	5.98e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—AKT1—prostate cancer	2.18e-06	5.96e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL6—prostate cancer	2.17e-06	5.93e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—AKT1—prostate cancer	2.16e-06	5.9e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—AKT1—prostate cancer	2.15e-06	5.88e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—AKT1—prostate cancer	2e-06	5.47e-06	CbGpPWpGaD
